Gliobastoma + New View on Clinical Trials... Dr. Fahar Merchant, President & CEO Medicenna Therapeutics

episode

BioTech Nation ... with Dr. Moira Gunn not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Montreal Canadiens Play-by-Play Victor Findlay (9/24/26) 17 min · 24 Sep 2026 · Oilers NOW with Bob Stauffer

Could Tom Beat 100 8-Year-Olds? 22 min · 24 Sep 2026 · Wolf & Owl with Romesh Ranganathan and Tom Davis

BITESIZE | The Truth About Stress: How to Reduce Overwhelm & Feel Calmer Every Day | Dr Rangan Chatterjee #682 26 min · 24 Sep 2026 · Feel Better, Live More with Dr Rangan Chatterjee

The Wind in the Rose-Bush by Mary E Wilkins Freeman 1h 3m · 24 Sep 2026 · Classic Ghost Stories

H4 Mike Sando, The Kicker 44 min · 24 Sep 2026 · The Program

What A Time To Be Alive! - Marina Hyde [EXCLUSIVE EXTRACT] 56 min · 24 Sep 2026 · The Rest Is Entertainment

Report any issue

Source

Recorded16 Aug 2023

Publisherfeeds.transistor.fm ↗

Handlerec:13349849

Show notes

Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in